Merrimack recruits Sanofi vet Richard Peters for the top job; ObsEva and Braeburn detail their IPO shots
• Now that Merrimack Pharmaceuticals $MACK has auctioned off its sole commercial drug to Ipsen and focused squarely on a set of top clinical candidates, the Cambridge, MA-based biotech has recruited longtime industry veteran Richard Peters to take the helm. The Harvard-trained physician is coming over from Sanofi Genzyme, where he was SVP of global rare diseases, a $3 billion per year business. “With the support of the Board of Directors and the expected near-term infusion of capital, several compelling clinical assets are now primed to realize their full potential,” said Peters in a statement. “Together with the rest of the management team, we plan on continuing to take substantial steps to grow our robust pipeline to its full potential, with an eye toward early data read-outs, to maximize value creation for patients and stockholders.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.